<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175731</url>
  </required_header>
  <id_info>
    <org_study_id>2017037-QILU</org_study_id>
    <nct_id>NCT03175731</nct_id>
  </id_info>
  <brief_title>PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)</brief_title>
  <acronym>PPIs</acronym>
  <official_title>A Randomized Controlled Study on the Effects of PPIs on Gastroesophageal Variceal Bleeding in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanjing Gao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver
      cirrhosis. Half of participants will receive PPI, while the other half will receive a
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PPIs can inhibit parietal cell H+/K+-ATPase and reduce secretion of gastric acid. PPIs can
      promote platelet aggregation and stabilize the formation of fibrin thrombosis by maintaining
      the high pH environment in the stomach and inactivating pepsin. The effect of PPIs on
      ulcerative upper gastrointestinal bleeding was confirmed but it is not clear whether PPIs is
      applicable in esophagogastric variceal bleeding whose etiology and bleeding position are
      different from ulcerative upper gastrointestinal bleeding. There is lack of consensus and
      sufficient evidences to support to use PPIs in esophagogastric variceal bleeding in cirrhotic
      patients universally. Nevertheless, the use of PPIs in liver cirrhotic patients with
      gastroesophageal varices is common.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Rate of esophagogastric variceal bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>8 weeks</time_frame>
    <description>Prognosis of esophagogastric variceal bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse eventsafter endoscopic therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Advers events include chest pain, dysphagia, fever and so on</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hypertension, Portal</condition>
  <arm_group>
    <arm_group_label>Proton Pump Inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole or Pantoprazole(or other PPIs) 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton Pump Inhibitors</intervention_name>
    <description>Esomeprazole or Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
    <arm_group_label>Proton Pump Inhibitors</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of cirrhosis

          -  GEVs was diagnosed by endoscopy

        Exclusion Criteria:

          -  Acute gastrointestinal bleeding need emergency surgery

          -  Acid-related disease, such as peptic ulcer disease or gastroesophageal reflux diseases
             (GERD)

          -  Hepatocellular carcinoma (HCC) or other malignant tumor

          -  History of esophagus, stomach or liver surgery

          -  Child-Pugh C and can't be improved to Child-Pugh A or B

          -  Preparing to be pregnant, pregnant or breast feeding

          -  Allergic to PPIs(proton pump inhibitors) or intolerable

          -  Cannot provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanjing /A Gao, PhD.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital,Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology,Qilu Hospital,Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Yanjing Gao</investigator_full_name>
    <investigator_title>Vice presidengt of Department of Gastroenterology of Qilu Hospital</investigator_title>
  </responsible_party>
  <keyword>Gastroesophageal varices</keyword>
  <keyword>Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

